Regeneron Pharmaceuticals, Inc. (REGN) To Go Ex-Dividend on February 20th

Posted by Alanna Baker on Feb 1st, 2026

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) declared a quarterly dividend on Friday, January 30th. Stockholders of record on Friday, February 20th will be paid a dividend of 0.94 per share by the biopharmaceutical company on Thursday, March 5th. This represents a c) dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date is Friday, February 20th. This is a 6.8% increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88.

Regeneron Pharmaceuticals has a dividend payout ratio of 8.9% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Regeneron Pharmaceuticals to earn $38.02 per share next year, which means the company should continue to be able to cover its $3.52 annual dividend with an expected future payout ratio of 9.3%.

Regeneron Pharmaceuticals Trading Down 1.1%

NASDAQ REGN opened at $741.45 on Friday. The company has a quick ratio of 3.33, a current ratio of 4.06 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $77.93 billion, a P/E ratio of 17.76, a P/E/G ratio of 1.95 and a beta of 0.39. Regeneron Pharmaceuticals has a 52-week low of $476.49 and a 52-week high of $821.11. The firm has a 50-day moving average price of $758.39 and a 200 day moving average price of $650.56.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last announced its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. The company had revenue of $3.88 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The firm’s revenue for the quarter was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $12.07 EPS. Equities research analysts expect that Regeneron Pharmaceuticals will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

Positive Sentiment: Company beat Q4 revenue and EPS estimates (qtrly revenue $3.88B; EPS $11.44 vs. consensus ~$10.74), helped by Dupixent and Eylea HD sales — a near-term fundamental driver supporting the stock. GlobeNewswire – Q4 Results
Positive Sentiment: Board raised the quarterly dividend to $0.94 (a ~6.8% increase vs. prior $0.88), signaling confidence in cash flow and making the stock slightly more attractive to income-focused investors.
Positive Sentiment: Analyst optimism persists — Raymond James reiterated a Buy and set an $870 target; Evercore/ISI and others have also lifted targets, which can support demand on dips. TipRanks – Raymond James
Positive Sentiment: Pipeline update: management highlighted an experimental obesity drug with added cholesterol-lowering benefits that could differentiate it in a crowded market — a potential medium-term growth driver. Reuters – Obesity drug story
Neutral Sentiment: Full earnings materials and the Q4 earnings call transcript are available for deeper detail — useful for investors who want guidance commentary and pipeline timing. Seeking Alpha – Call Transcript
Negative Sentiment: Despite the beats, EPS declined year-over-year (from $12.07 to $11.44) as higher expenses weighed on profitability — a headline that likely pressured sentiment. Reuters – Profit beat but EPS down YoY
Negative Sentiment: Core Eylea weakness and investor concerns about sustainability of growth prompted some sell-side caution and profit-taking even after the beat, which helps explain the share decline today. MSN – Why shares fell

Regeneron Pharmaceuticals Company Profile

(Get Free Report)

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.